ClinicalTrials.gg
RecruitingNCT06726109FOCUS-ADHFUpdated May 6, 2025

The FOCUS-ADHF Registry

An observational study in Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive and Regurgitation, Mitral, sponsored by ASL Città di Torino. Recruiting at 4 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by ASL Città di Torino · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.

Planned enrollment
9th of 33
600 · median 200
Started
2025
with 5 others
Observational
33 of 63
11 open now
Primary completion
2030-04
later than 23 of 27 live
Registered
56th of 63
by date
Lead sponsor
1 of 63
ASL Città di Torino

Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 9th largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2025, is one of 33 observational ones, reaches primary completion later than 23 of the 27 other live ones, and was the 56th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Mitral Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

Acute heart failure (AHF) represents a significant clinical and economic burden due to its impact on patients' quality of life, poor prognosis, and high healthcare costs. Despite advancements in treatment, the optimal therapeutic management of these patients, particularly those with severely reduced ejection fraction and dilated left ventricles, remains uncertain. The last European Society of Cardiology (ESC) guidelines gave a weak recommendation for using intravenous (IV) vasodilators in patients with adequate systolic blood pressure. This is derived from heterogeneous randomized controlled trials (RCTs) enrolling all-comers heart failure patients. Those studies did not specifically target conditions that from a pathophysiological perspective might derive potential positive response from vasodilators like left ventricle dilatation, significant mitral regurgitation and/or increased filling pressure. Patients with such characteristics show higher myocardial wall tension and are particularly vulnerable to afterload increases, positioning them as optimal candidates for vasodilator therapy during acute decompensation. Little evidence is available from real world cohort study on the benefit of vasodilators in this group of patients. Many of these studies used pre-defined protocol and invasive hemodynamic monitoring. On the contrary the use of echocardiographic evaluation to phenotype, infer hemodynamic parameters and assess treatment effect has become the most common adopted technique in real life.

The present prospective registry aims to investigate acute treatment management and outcomes in a focused population of patients admitted for an acute decompensation of heart failure (ADHF) with severely reduced ejection fraction and dilated left ventricle or significant functional mitral regurgitation.

Inclusion Criteria:

  • Patients within 24h since admission for an ADHF defined as

    1. signs and symptoms of volume overload with necessity of iv diuretic treatment.
    2. and NT-proBNP (N-terminal pro-B-type natriuretic peptide) >1500 pg/mL or a B-type natriuretic peptide level of >500 ng/mL.

      • Admission echocardiography with evidence of a dilated left ventricle and/or at least moderate functional mitral regurgitation (FMR), reduced ejection fraction (\<40%), increased LV (II/III degree diastolic dysfunction) and pulmonary pressure (sPAP ≥ 40 mmHg or MPAP ≥ 20 mmHg).

      Exclusion Criteria:

      • Cardiogenic shock at admission warranting immediate MCS / inotropic support, severe renal or hepatic impairment, recent myocardial infarction, and other terminal illnesses.
      • Use of vasopressors/inotropes or mechanical support at admission. Methods Patients will receive treatments according to their physician's discretion based on ESC guidelines. Serial evaluations of heart function will be conducted using echocardiography and lung ultrasound (LUS) at multiple time points as well as hemodynamic data, laboratory and HF medications' prescription and dosages Primary endpoint

        • 3 months incidence of need of Heart Replacement Therapies (LVAD or heart transplantation) and/or heart failure re-hospitalization and/or all-cause death.

      Secondary endpoints • In hospital and 3 months All-cause death

      • All cause and HF related hospitalizations within 3 months
      • Heart replacement therapies (LVAD or heart transplantation) within 3 months.
      • In hospital Worsening Heart Failure (WHF)
      • Need of renal replacement therapy (RRT) within 3 months
      • In-hospital length of stay (days), NT-proBNP variations, GDMT and diuretics prescription and dosages up to three months;

      Objectives:

    <!-- -->

    1. To describe the acute therapeutic management and discharge prescriptions for heart failure medications, including doses, in a selected population with ADHF.
    2. To evaluate clinical outcomes and NT-proBNP variation in relation to initial intravenous medications, particularly comparing the use versus non-use of vasodilators.
    3. To identify the incidence and timing of a significant therapeutic response through serial evaluations of LUS and echo-derived parameters, and to examine their association with the initial intravenous medications prescribed.
    4. To investigate the association between the criteria for therapeutic response and clinical outcomes in both short- and medium-term follow-up, with a focus on the relationship to the initially administered therapy.
Read the detailed description

This is a real-life, observational, prospective multicenter registry. Patients fulfilling inclusion and exclusion criteria will be consecutively enrolled in enrolling center.

Enrolled patients will be treated at each treating physician's discretion referring to the general recommendation of the last ESC guidelines on management of acute heart failure as well as local practice. General guidelines for vasodilators use will be shared among enrolling centers to increase uniformity of treatment in case of prescription of this strategy.

-After achievement of adequate decongestion, iv vasodilators infusion (if used) will be weaned and HF medications introduction/titration up to guidelines recommended doses.

Other therapeutic interventions: will be left to treating physician discretion aiming to decongest the patient.

Starting inotropes, vasopressors, mechanical cardiac support device (MCS) and use of non-invasive and/or invasive ventilation as well as continuous renal replacement therapies (CRRT) will be left to the treating physicians' discretion according to clinical course.

03

Conditions studied

  • Acute Heart Failure With Reduced Ejection Fraction
  • Decompensation; Heart, Congestive
  • Regurgitation, Mitral

Keywords

  • Acute Heart Failure (AHF)
  • Acute Decompensated Heart Failure (ADHF)
  • Vasodilators
  • Dilated left ventricle
  • reduced ejection fraction (rEF)
  • functional mitral regurgitation (FMR)
  • increased filling pressure
  • increased pulmonary artery pressure
  • nitroprusside
  • sodium nitroprusside
  • Isosorbide Dinitrate
  • nitroglycerine
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All-comers patients admitted for an ADHF with a severely reduced ejection fraction, a dilated left ventricle or significant functional mitral regurgitation (FMR) and increased left ventricle filling and pulmonary pressures as estimated by echocardiographic evaluation at admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients within 24h since admission for an acute decompensation of heart failure (ADHF)* (both acute on chronic and de novo) defined as

    1. signs and symptoms of volume overload with necessity of iv diuretic treatment.
    2. and NT-proBNP (N-terminal pro-B-type natriuretic peptide) >1500 pg/mL or a B-type natriuretic peptide level of >500 ng/mL.

AND ALL THE FOLLOWING echo entry criteria at admission:

  1. A dilated left ventricle (defined as a indexed LVEDD ≥ 31 mm/sm and ≥ 32 mm/sm or a indexed LVEDVol ≥ 75 ml/sm and ≥ 62 ml/sm in men and women respectively) AND/OR at least moderate functional mitral regurgitation (FMR).
  2. Reduced (\<40%)
  3. Increased LV filling pressure (defined as II°-III° Diastolic dysfunction) AND increased pulmonary artery pressure (i.e. echo estimated systolic pulmonary artery pressure [sPAP] ≥ 40 mmhg and/or echo estimated mean pulmonary artery pressure [mPAP] ≥ 20 mmHg).

Exclusion criteria

Exclusion Criteria:

  • Patients presenting in Cardiogenic shock defined as hypotension (SBP \< 90mmHg or MAP ≤ 55) AND hypoperfusion (defined as arterial lactates > 4 mmol/L)
  • Estimated \<=20 ml/min/1.73 m2 or in chronic renal replacement therapies.
  • End-stage hepatic impairment
  • Use of temporary mechanical support at the moment of study inclusion or planned to use it within hours (IABP; Impella, VA ECMO)
  • Ongoing treatment with vasopressors/inotropes at the moment of randomization or administration of Levosimendan within 30 days before randomization. Patients admitted for a planned cycle of Levosimendan infusion will be excluded by the present study as well.
  • AHF secondary to recent onset tachy-arrhythmias
  • ST tract elevated myocardial infarction (STEMI) \< 30 days, myocarditis \<30 days, AHF due to severe primary valve disease or clinical suspicion of an acute mechanical cause of AHF
  • restrictive cardiomyopathy, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, tako-tsubo syndrome
  • Infective endocarditis, concomitant active septic disease as predominant cause of decompensation or admission TC>38°c.
  • LVAD carriers or Heart transplant recipients
  • Terminal illness other than heart failure with an expected survival \<180 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • vasodilator treated

    patients treated with vasodilator therapy after admission for an ADHF episode

  • Not vasodilator treated

    Patients not treated with vasodilator therapy after admission for an ADHF episode

06

What researchers measure

Primary outcomes

  1. incidence of need of Heart Replacement Therapies (LVAD or heart transplantation) and/or heart failure re-hospitalization and/or all-cause death.

    Time frame: from enrollment up to 3 months

Secondary outcomes

  1. incidence of all-cause mortality

    Time frame: from enrollment up to 3 months

  2. incidence of HF related hospitalizations

    Time frame: from enrollment up to 3 months

  3. incidence of all-cause hospitalization

    Time frame: from enrollment up to 3 months

  4. incidence of patients needing heart replacement therapies (LVAD or heart transplantation)

    Heart transplantation or LVAD implantation

    Time frame: from enrollment up to 3 months

  5. incidence of In hospital Worsening Heart Failure (WHF)

    need for therapeutic intensification for inadequate clinical response

    Time frame: from date of enrollment until the date of first worsening heart failure event or the date of death from any cause or the date of hospital discharge, whichever came first, assessed up to 3 months

  6. incidence of patients needing renal replacement therapy (RRT)

    need for use of renal replacement therapy

    Time frame: from enrollment up to 3 months

  7. rate of GDMT and diuretics prescription and dosages

    prescription of 4 hf pillars, Vericiguat, diuretics and doses

    Time frame: from admission up to 3 months follow-up

07

Study locations

4 of 4 sites recruiting
  • division of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium. Hasselt University, Belgium.
    Genk, Belgium
    Recruiting
    • Wilfred Mullens, MD, Prof. · Principal investigator
  • Rivoli Hospital
    Rivoli, Italy
    Recruiting
    • Alessandro Galluzzo, MD · Contactalegallu@yahoo.it
    • Alessandro Galluzzo, MD · Principal investigator
  • San Giovanni Bosco Hospital
    Turin, 10154, Italy
    Recruiting
  • Santa Maria della Misericordia, Azienda sanitaria universitaria Friuli Centrale,
    Udine, Italy
    Recruiting
    • Davide Stolfo, MD,PhD · Contact
08

References and documents

Publications

  • Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Miro O, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. Eur J Heart Fail. 2019 Jul;21(7):844-851. doi: 10.1002/ejhf.1499. Epub 2019 Jun 19. PubMed 31218825 ↗
  • Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes-Genis A, Abdelhamid M, Adamopoulos S, Anker SD, Bauersachs J, Belenkov Y, Bohm M, Gal TB, Butler J, Cohen-Solal A, Filippatos G, Gustafsson F, Hill L, Jaarsma T, Jankowska EA, Lainscak M, Lopatin Y, Lund LH, McDonagh T, Milicic D, Moura B, Mullens W, Piepoli M, Polovina M, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Sharma R, Thum T, Tocchetti CG, Van Linthout S, Vitale C, Von Haehling S, Volterrani M, Coats AJS, Chioncel O, Rosano G. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail. 2023 Jul;25(7):1115-1131. doi: 10.1002/ejhf.2888. Epub 2023 Jul 13. PubMed 37448210 ↗
  • Gentile F, Buoncristiani F, Sciarrone P, Bazan L, Panichella G, Gasparini S, Chubuchny V, Taddei C, Poggianti E, Fabiani I, Petersen C, Lancellotti P, Passino C, Emdin M, Giannoni A. Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation. Int J Cardiol. 2023 Dec 1;392:131272. doi: 10.1016/j.ijcard.2023.131272. Epub 2023 Aug 19. PubMed 37604287 ↗
  • Frea S, Gravinese C, Boretto P, De Lio G, Bocchino PP, Angelini F, Cingolani M, Gallone G, Montefusco A, Valente E, Pidello S, Raineri C, De Ferrari GM. Comprehensive non-invasive haemodynamic assessment in acute decompensated heart failure-related cardiogenic shock: a step towards echodynamics. Eur Heart J Acute Cardiovasc Care. 2024 Sep 25;13(9):646-655. doi: 10.1093/ehjacc/zuae087. PubMed 39012797 ↗
  • Bertaina M, Galluzzo A, Rossello X, Sbarra P, Petitti E, Prever SB, Boccuzzi G, D'Ascenzo F, Frea S, Pidello S, Morici N, Sacco A, Oliva F, Valente S, De Ferrari GM, Ugo F, Rametta F, Attisani M, Zanini P, Noussan P, Iannaccone M. Prognostic implications of pulmonary artery catheter monitoring in patients with cardiogenic shock: A systematic review and meta-analysis of observational studies. J Crit Care. 2022 Jun;69:154024. doi: 10.1016/j.jcrc.2022.154024. Epub 2022 Mar 25. PubMed 35344825 ↗
  • Hill JA, Pauly DF, Olitsky DR, Russell S, O'Connor CM, Patterson B, Elkayam U, Khan S, Stevenson LW, Brooks K, Wagoner L, Conway G, Koelling T, Huysen C Van, Hare J, Breton E, Adams KF, Glotzer J, Fonarow G, Hamilton M, Sorg J, Drazner M, Hoffman S, Miller LW, Graziano JA, Berman ME, Frantz R, Hartman K, Leier C V., Abraham WT, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness. J Am Med Assoc 2005;294:1625-1633.
  • Verbrugge FH, Dupont M, Finucan M, Gabi A, Hawwa N, Mullens W, Taylor DO, Young JB, Starling RC, Tang WH. Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. Eur J Heart Fail. 2015 Sep;17(9):956-63. doi: 10.1002/ejhf.324. Epub 2015 Jul 24. PubMed 26213182 ↗
  • Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008 Jul 15;52(3):200-7. doi: 10.1016/j.jacc.2008.02.083. PubMed 18617068 ↗
  • Garatti L, Frea S, Bocchino PP, Angelini F, Cingolani M, Sacco A, Rondinara GM, Bagnardi V, Sala IM, Kapur NK, Colombo PC, De Ferrari GM, Morici N. Sodium nitroprusside in acute heart failure: A multicenter historic cohort study. Int J Cardiol. 2022 Dec 15;369:37-44. doi: 10.1016/j.ijcard.2022.08.009. Epub 2022 Aug 6. PubMed 35944767 ↗
  • Freund Y, Cachanado M, Delannoy Q, Laribi S, Yordanov Y, Gorlicki J, Chouihed T, Feral-Pierssens AL, Truchot J, Desmettre T, Occelli C, Bobbia X, Khellaf M, Ganansia O, Bokobza J, Balen F, Beaune S, Bloom B, Simon T, Mebazaa A. Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial. JAMA. 2020 Nov 17;324(19):1948-1956. doi: 10.1001/jama.2020.19378. PubMed 33201202 ↗
  • Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Muller B, Noveanu M, Socrates T, Ziller R, Bayes-Genis A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Munzel T, Erne P, Mueller C; GALACTIC Investigators; Mueller C, Erne P, Muller B, Rickli H, Maeder M, Tavares de Oliveira M Jr, Munzel T, Bayes-Genis A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vogele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vogele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA. 2019 Dec 17;322(23):2292-2302. doi: 10.1001/jama.2019.18598. PubMed 31846016 ↗
  • Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, et al. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med N Engl J Med; 2019;381:716-726.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P Van Der, Sisakian HS, Isayev E, Kurlianskaya A, Mullens W, Tokmakova M, Agathangelou P, Melenovsky V, Wiggers H, Hassanein M, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-2200m.
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J Oxford Academic; 2021;42:3599-3726.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2030, 60 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 60 months is close to that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 10, 2024
StartActual
Apr 27, 2025
Primary completionEst.
Apr 2030
CompletionEst.
Aug 2030
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06726109
Lead sponsor
ASL Città di Torino
Collaborators
Hospital of Rivoli, Ziekenhuis Oost-Limburg
Responsible party
Maurizio Bertaina (Medical Doctor, Principal Investigator, Ospedale S. Giovanni Bosco) — Principal investigator
First posted
Dec 10, 2024
Start date
Apr 27, 2025
Primary completion
Apr 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
May 6, 2025

Study contacts

Maurizio Bertaina, MD
Contact
maurizio.bertaina@gmail.com
+393464300039
Maurizio Bertaina, MD
principal investigator · Division of Cardiology, San Giovanni Bosco,ASL Città di Torino, Turin, Italy
Wilfred Mullens, MD,Prof.
principal investigator · Division of Cardiology,Ziekenhuis Oost-Limburg, Genk, Belgium. Hasselt University, Belgium.
Alessandro Galluzzo, MD
principal investigator · Division of cardiology, Rivoli Hospital, Rivoli, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion